Wendy W Wu

发表

A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.

Phu N. Tran, T. Colatsky, Zhihua Li, 2016, Journal of pharmacological and toxicological methods.

Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel–Drug Binding Kinetics and Multichannel Pharmacology

Kelly C. Chang, Phu N. Tran, T. Colatsky, 2017, Circulation. Arrhythmia and electrophysiology.

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block

Phu N. Tran, D. Strauss, Jiansong Sheng, 2020, PloS one.

Drug potency on inhibiting late Na+ current is sensitive to gating modifier and current region where drug effects were measured.

Phu N. Tran, Jiansong Sheng, Wendy W Wu, 2019, Journal of pharmacological and toxicological methods.

Effects of sex hormones on cardiac ion channels involved in ventricular repolarization

Wendy W Wu, 2020 .

hERG block potencies for 5 positive control drugs obtained per ICH E14/S7B Q&As best practices: Impact of recording temperature and drug loss.

Wendy W Wu, Vikram Patel, M. Matta, 2022, Journal of pharmacological and toxicological methods.

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)

D. Strauss, Zhihua Li, Wendy W Wu, 2020, Clinical pharmacology and therapeutics.

quantification reveals the importance of data variability and experimental design considerations for in silico

Kelly C. Chang, Phu N. Tran, T. Colatsky, 2017 .

Quantitative analysis of underivatized 17 β-estradiol using a high-throughput LC-MS/MS assay - Application to support a pharmacokinetic study in ovariectomized guinea pigs.

Wendy W Wu, Vikram Patel, M. Matta, 2020, Journal of pharmaceutical and biomedical analysis.

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science

D. Strauss, Zhihua Li, Wendy W Wu, 2023, Frontiers in Medicine.

A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model.

James Kramer, David G Strauss, George Okeyo, 2020, Journal of pharmacological and toxicological methods.

A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm

James Kramer, David G Strauss, Liudmila Polonchuk, 2020, Toxicology and applied pharmacology.

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Min Wu, James Kramer, Gary R. Mirams, 2018, Clinical pharmacology and therapeutics.

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment

Min Wu, Zhihua Li, Gary R. Mirams, 2017, Front. Physiol..

Experimental factors that impact CaV1.2 channel pharmacology—Effects of recording temperature, charge carrier, and quantification of drug effects on the step and ramp currents elicited by the “step-step-ramp” voltage protocol

Phu N. Tran, Jiansong Sheng, Wendy W Wu, 2022, PloS one.

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

Gary Gintant, David G. Strauss, Jose Vicente, 2019, Therapeutic innovation & regulatory science.

Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity.

Kelly C. Chang, Phu N. Tran, T. Colatsky, 2017, Journal of pharmacological and toxicological methods.

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

Kelly C. Chang, Phu N. Tran, T. Colatsky, 2017, Front. Physiol..